|
1
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gisselbrecht C, Glass B, Mounier N, et al:
Salvage regimens with autologous transplantation for relapsed large
B-cell lymphoma in the rituximab era. J Clin Oncol. 28:4184–4190.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feugier P, Virion JM, Tilly H, Haioun C,
Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T,
Lederlin P and Coiffier B: Incidence and risk factors for central
nervous system occurrence in elderly patients with diffuse
large-B-cell lymphoma: influence of rituximab. Ann Oncol.
15:129–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boehme V, Schmitz N, Zeynalova S, Loeffler
M and Pfreundschuh M: CNS events in elderly patients with
aggressive lymphoma treated with modern chemotherapy (CHOP-14) with
or without rituximab: an analysis of patients treated in the
RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma
study group (DSHNHL). Blood. 113:3896–3902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bernstein SH, Unger JM, Leblanc M,
Friedberg J, Miller TP and Fisher RI: Natural history of CNS
relapse in patients with aggressive non-Hodgkin's lymphoma: a
20-year follow-up analysis of SWOG 8516-the southwest oncology
group. J Clin Oncol. 27:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bierman P and Giglio P: Diagnosis and
treatment of central nervous system involvement in non-Hodgkin's
lymphoma. Hematol Oncol Clin North Am. 19:597–609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hegde U, Filie A, Little RF, Janik JE,
Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A,
Stetler-Stevenson M and Wilson WH: High incidence of occult
leptomeningeal disease detected by flow cytometry in newly
diagnosed aggressive B-cell lymphomas at risk for central nervous
system involvement: the role of flow cytometry vs. cytology. Blood.
105:496–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coiffier B, Lepage E, Briere J, et al:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.
346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coiffier B, Thieblemont C, Van Den Neste
E, et al: Long-term outcome of patients in the LNH-98.5 trial, the
first randomized study comparing rituximab-CHOP to standard CHOP
chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des
Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pfreundschuh M, Trumper L, Osterborg A, et
al: MabThera International Trial Group: CHOP-like chemotherapy plus
rituximab vs. CHOP-like chemotherapy alone in young patients with
good prognosis diffuse large-B-cell lymphoma: a randomised
controlled trial by the MabThera International Trial (MInT) Group.
Lancet Oncol. 7:379–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pfreundschuh M, Schubert J, Ziepert M, et
al: German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL):
Six versus eight cycles of bi-weekly CHOP-14 with or without
rituximab in elderly patients with aggressive CD20+
B-cell lymphomas: a randomized controlled trial (RICOVER-60).
Lancet Oncol. 9:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boehme V, Zeynalova S, Kloess M, Loeffler
M, Kaiser U, Pfreundschuh M and Schmitz N: German High-Grade
Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk
factors of central nervous system recurrence in aggressive lymphoma
- a survey of 1693 patients treated in protocols of the German
High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol.
18:149–157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimazu Y, Notohara K and Ueda Y: Diffuse
large B-cell lymphoma with central nervous system relapse:
prognosis and risk factors according to retrospective analysis from
a single-center experience. Int J Hematol. 89:577–583. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Villa D, Connors JM, Shenkier TN, Gascoyne
RD, Sehn LH and Savage KJ: Incidence and risk factors for central
nervous system relapse in patients with diffuse large B-cell
lymphoma: the impact of the addition of rituximab to CHOP
chemotherapy. Ann Oncol. 21:1046–1052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kridel R and Dietrich PY: Prevention of
CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol.
12:1258–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jahnke K, Thiel E, Martus P, Schwartz S
and Korfel A: Retrospective study of prognostic factors in
non-Hodgkin lymphoma secondarily involving the central nervous
system. Ann Hematol. 85:45–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomita N, Yokoyama M, Yamamoto W, et al:
Central nervous system event in patients with diffuse large B-cell
lymphoma in rituximab era. Cancer Sci. 103:245–251. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rubenstein JL, Combs D, Rosenberg J, Levy
A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D,
Grillo-Lopez A and Shuman MA: Rituximab therapy for CNS lymphomas:
targeting the leptomeningeal compartment. Blood. 101:466–468. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doolittle ND, Abrey LE, Shenkier TN, et
al: Brain parenchyma involvement as isolated central nervous system
relapse of systemic non-Hodgkin lymphoma: an international primary
CNS lymphoma collaborative group report. Blood. 111:1085–1093.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won
JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS and Suh C: Secondary
central nervous system (CNS) involvement in patients with diffuse
large B-cell lymphoma: a therapeutic dilemma. Ann Hematol.
90:539–546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gavrilovic IT, Hormigo A, Yahalom J,
DeAngelis LM and Abrey LE: Long-term follow-up of high-dose
methotrexate-based therapy with and without whole brain irradiation
for newly diagnosed primary CNS lymphoma. J Clin Oncol.
24:4570–4574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bromberg JE, Doorduijn JK, Illerhaus G,
Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van
Montfort C and van den Bent MJ: Central nervous system recurrence
of systemic lymphoma in the era of stem cell transplantation - an
international primary central nervous system lymphoma study group
project. Haematologica. 98:808–813. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chua SL, Seymour JF, Streater J, Wolf MM,
Januszewicz EH and Prince HM: Intrathecal chemotherapy alone is
inadequate central nervous system prophylaxis in patients with
intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma.
43:1783–1788. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arkenau HT, Chong G, Cunningham D, Watkins
D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A and
Horwich A: The role of intrathecal chemotherapy prophylaxis in
patients with diffuse large B-cell lymphoma. Ann Oncol. 18:541–545.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tai WM, Chung J, Tang PL, Koo YX, Hou X,
Tay KW, Quek R, Tao M and Lim ST: Central nervous system (CNS)
relapse in diffuse large B cell lymphoma (DLBCL): pre- and
post-rituximab. Ann Hematol. 90:809–818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmitz N, Zeynalova S, Glass B, Kaiser U,
Cavallin-Stahl E, Wolf M, Haenel M, Loeffler M, Truemper L and
Pfreundschuh M: CNS disease in younger patients with aggressive
B-cell lymphoma: an analysis of patients treated on the Mabthera
international trial and trials of the German high-grade non-Hodgkin
lymphoma study group. Ann Oncol. 23:1267–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shapiro WR, Young DF and Mehta BM:
Methotrexate: distribution in cerebrospinal fluid after
intravenous, ventricular and lumbar injections. N Engl J Med.
293:161–166. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kwong YL, Yeung DY and Chan JC:
Intrathecal chemotherapy for hematologic malignancies: drugs and
toxicities. Ann Hematol. 88:193–201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hegde U, Filie A, Little RF, Janik JE,
Grant N and Steinberg SM: High incidence of occult leptomeningeal
disease detected by flow cytometry in newly diagnosed aggressive
B-cell lymphomas at risk for CNS involvement: the role of flow
cytometry vs. cytology. Blood. 105:496–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abramson JS, Hellmann M, Barnes JA,
Hammerman P, Toomey C, Takvorian T, Muzikansky A and Hochberg EP:
Intravenous methotrexate as central nervous system (CNS)
prophylaxis is associated with a low risk of CNS recurrence in
high-risk patients with diffuse large B-cell lymphoma. Cancer.
116:4283–4290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheah CY, Herbert KE, O'Rourke K, et al: A
multicentre retrospective comparison of central nervous system
prophylaxis strategies among patients with high-risk diffuse large
B-cell lymphoma. Br J Cancer. 111:1072–1079. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holte H, Leppa S, Bjorkholm M, et al:
Dose-densified chemoimmunotherapy followed by systemic central
nervous system prophylaxis for younger high-risk diffuse large
B-cell/follicular grade 3 lymphoma patients: results of a phase II
Nordic lymphoma group study. Ann Oncol. 24:1385–1392. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamamoto W, Tomita N, Watanabe R, Hattori
Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S and Ishigatsubo Y:
Central nervous system involvement in diffuse large B-cell
lymphoma. Eur J Haematol. 85:6–10. 2010.PubMed/NCBI
|
